ROARABLE
FREE $100K
Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / BIO / insiders
TXG (59) AVTR (56) BRKR (54) RVTY (65) ⌘ Pro Terminal β†’

Bio-Rad Laboratories Inc. (BIO) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$366.16 -1.62% NYSE β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $364.40

Bio-Rad Laboratories Inc. (BIO) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C β€’ HOLD / WATCH Cap $9.95B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BIO Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Bio-Rad Laboratories Inc. (NYSE: BIO) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $366.16 (-1.62% 1D, market cap $9.95B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, BIO ranks #146 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BIO compare to TXG and AVTR in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), BIO carries a Roarable C (62/100 RQD), trailing P/E of 13.5x, gross margin of 51.9%, and ROIC of 0.5%. By comparison, TXG (10x Genomics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B) and AVTR (Avantor Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BIO?
β–Ό

Per BIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000012208), Bio-Rad Laboratories Inc. generated $2.58B in revenue (+0.7% YoY), $759.9M in net income, and $374.6M in free cash flow against $10.58B in total assets and $1.20B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $364.40 (-0.48%)🧬 Cannibal Buyback (-1.80% YoY Shares)βš™οΈ Cash Engine: 7/20 (D-) β€’ 14.5% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY β€’ 54.3% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERHOLD / WATCH β€’ C
025507510062
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ Β· Rk B-
Cash (7)Whales (13)SEC (16)Macro (12)CEO (14)
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
$440 Bull$373 Base$291 Bear
πŸ“¬ FREE BIO RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BIO)Realized 20D OHLCV Swing Band: Β±6.2%
Deterministic 5-Pillar Attribution (62/100 Composite)
πŸ” WHY BIO SCORES 62/100 (C) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (26% of score)

Altman Z-Score 3.59 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 7/9

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+14/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 70% Net Buy β€’ Cannibal Buyback (-1.80% YoY Shares)

β–Ό #1 Drag / Risk Factor: Cash Engine Quality7/20 pts (-13 pt drag)

Capital intensity & 1.8% operating margin leave 13 pts on the table

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
54
Grade C-$362.43-0.5% Next Q
Q2 (-2Q)
57
Grade C$360.50+6.8% Next Q
Q3 (-1Q)
59
Grade C$385.12-4.9% Next Q
Current
62
Grade C$366.16+0.7% Hist 90D Ξ±
Trajectory: C- (54) β†’ C (62)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the BIO Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 62/100 (C) score, BIO faces multiple-compression risk if 13.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.80% YoY Shares) β€” any gross margin slip below 49.4% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($374.58) or 200D SMA ($314.37) invalidates the momentum regime and cuts Target Base ($372.75) toward Bear Floor ($290.75).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BIOβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBIO Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 62%NO 38%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

BIO Smart-Money Thermometer: HEAVY INSIDER & 13F ACCUMULATION

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BIO)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BIO. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (BIO Tape Review)

  • βœ“Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • βœ“Forensic Red-Light accounting & dilution traps to review on your watchlist
  • βœ“Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BIO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +42.00%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $384.4H $384.4L $366.2C $366.2VOL 183.1K
RES: $389.6SUP: $356.6SMA50: $374.6SMA200: $314.4
$407.4$361.1$314.9$268.6$222.4RES $389.6SUP $356.6$366.22026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BIO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BIO Butterfly Map β†’ + Track BIO β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
5.0%/yr Implied 5Y Growth

vs. +0.7% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BIO today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BIO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BIO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIO)

Health Care Rank #146 of 1015 βš”οΈ TXG vs BIO Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BIO vs. TXG, AVTR, BRKR, RVTY)

Industry: Biotechnology: Laboratory Analytical Instruments (21 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Bio-Rad Laboratories Inc. (BIO) ranks #146 by composite RQD confidence (62/100, grade C) and #110 by equity capitalization ($9.95B). Within this direct 5-issuer industry benchmark cohort, BIO leads on earnings valuation at 13.5x trailing P/E, while RVTY leads on capital efficiency and profitability with 3.1% ROIC and β€” gross margin. RVTY currently holds the highest overall quantitative score in the immediate peer group at 65/100 (C) compared with BIO at 62/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BIO ACTIVE
Bio-Rad Laboratories Inc.
C 62/100 13.5x 51.9% 0.5% -1.62% $9.95B Benchmark Subject
TXG
10x Genomics Inc.
C- 59/100 β€” 69.1% -5.7% -12.09% $9.13B /txg-vs-bio β†’
AVTR
Avantor Inc.
D+ 56/100 β€” 32.7% -2.1% -2.74% $10.88B /avtr-vs-bio β†’
BRKR
Bruker Corporation
D+ 54/100 β€” 45.9% 1.3% -2.42% $8.70B /brkr-vs-bio β†’
RVTY
Revvity Inc.
C 65/100 76.7x β€” 3.1% -3.44% $17.52B /rvty-vs-bio β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0000012208 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bio-Rad Laboratories Inc. (BIO) reported GAAP revenue of $2.58B (+0.7% vs. FY2024 revenue of $2.57B , and -3.3% cumulative change since FY2023) , GAAP net income of $759.9M, operating cash flow of $532.2M, and free cash flow of $374.6M (+29.4% YoY). On the balance sheet, BIO closed FY2025 with $10.58B in total assets against $1.20B in total debt (Altman Z-Score: 3.59, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $2.58B $759.9M $532.2M $374.6M $10.58B $1.20B
FY2024 (FY) 2024-12-31 $2.57B -$1.84B $455.2M $289.6M $9.36B $1.20B
FY2023 (FY) 2023-12-31 $2.67B -$637.3M $374.9M $254.7M $5.65B $1.32B

3. BIO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BIO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Bio-Rad Laboratories Inc. (NYSE: BIO) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $366.16 (-1.62% 1D, market cap $9.95B). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 13/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 14/20. Across 1015 tracked Health Care issuers, BIO ranks #146 in composite RQD confidence.

How does BIO compare to TXG and AVTR in the Health Care sector?

Within the Health Care sector (Biotechnology: Laboratory Analytical Instruments), BIO carries a Roarable C (62/100 RQD), trailing P/E of 13.5x, gross margin of 51.9%, and ROIC of 0.5%. By comparison, TXG (10x Genomics Inc.) holds a C- grade (59/100 RQD, P/E N/A, ROIC -5.7%, cap $9.13B) and AVTR (Avantor Inc.) posts a D+ grade (56/100 RQD, P/E N/A, ROIC -2.1%, cap $10.88B). Among the 5-stock peer group, BIO leads on earnings multiple (13.5x) while RVTY leads on capital efficiency (3.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BIO?

Per BIO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000012208), Bio-Rad Laboratories Inc. generated $2.58B in revenue (+0.7% YoY), $759.9M in net income, and $374.6M in free cash flow against $10.58B in total assets and $1.20B in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BIO trading relative to its 50-day, 200-day, and 52-week technical levels?

BIO last traded at $366.16 (-1.62% on volume of 211,900 shares), positioning the stock -2.25% below its 50-day simple moving average ($374.58) and +16.47% above its 200-day simple moving average ($314.37). Across its 52-week range of $236.73 to $396.23, BIO sits at the 81.1% percentile with a 14-day RSI of 50.1 (NEUTRAL RANGE) and an implied next-earnings move of Β±6.2% ($343.46 to $388.86).

Direct Sub-Reports: BIO RQD Cockpit BIO 12M Forecast BIO Earnings & Move BIO Dividends & DRIP BIO Insiders & 13F BIO Whale Options BIO Profit Sankey BIO News & Why
ROARABLE RATING BRIEF β€’ RQD 62/100 (C) βœ“ SEC XBRL & RQD VERIFIED

BIO β€” Bio-Rad Laboratories Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Bio-Rad Laboratories Inc. (BIO) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $366.16 (-1.62% 1D, market capitalization $9.95B).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of 0.5%, gross margin of 51.9%, operating margin of 1.8%, and free cash flow yield of 3.64%.
  • Whale 13F & Options Flow (13/20) + Insider Conviction (14/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 1.04x equity beta, Altman Z-Score of 3.59, Piotroski F-Score of 7/9, and Debt/Equity of 0.16x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Bio-Rad Laboratories Inc. (BIO) is a NYSE-listed issuer in the Health Care sector, operating in the Biotechnology: Laboratory Analytical Instruments industry. The source data identifies the company's market capitalization as $10.3B. Revenue is reported in the SEC financials at $2.58B for FY 2025.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Bio-Rad Laboratories Inc. (BIO) reported $2.58B in annual revenue (up from $2.57B in FY2024, +0.7% YoY) and $759.9M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($2.67B revenue, -$637.3M net income) through FY2025, BIO scaled operating cash flow to $532.2M and free cash flow to $374.6M, backed by $10.58B in total assets against $1.20B in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (C β€’ RQD 62/100): Company leadership has skin in the game with net positive insider conviction. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 13/20, sustained execution supports upside toward the upper end of the $236.73 – $396.23 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 13.5x trailing P/E and 60.4x EV/EBITDA against 1.8% operating margins and a 1.04x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

The only sector context provided is Health Care / Biotechnology: Laboratory Analytical Instruments, and the beta of 1.04 per the market data. An investor should not infer specific supplier or customer ripple effects from the source material.

  • Key Question #1: Can BIO sustain or expand its 1.8% operating margin and 0.5% ROIC against Biotechnology: Laboratory Analytical Instruments peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $2.58B and free cash flow of $374.6M, how will capital allocation balance growth reinvestment against $1.20B in total debt?
  • Key Question #3: How sensitive is BIO's 12.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.04x)?

BIO Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Bio-Rad Laboratories Inc. (BIO) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BIO Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BIO Bull vs. Bear Conversation Board β€” What's Your Call at $366.16?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BIO 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BIO:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $457.78 (+23.0%)
πŸ“Œ Pinned Debate

Strong balance-sheet forensics (Altman Z 3.59, Piotroski F 7/9, Debt/Equity 0.16) and high institutional flow support the rating despit

The street is overcomplicating Bio-Rad Laboratories Inc. (BIO). Strong balance-sheet forensics (Altman Z 3.59, Piotroski F 7/9, Debt/Equity 0.16) and high institutional flow support the rating despite weak returns on capital.. With an RQD score of 62/100 (C) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $401.95.

SectorRotator πŸ‚ BULL

@RiskArb_Desk Fair point on 13.5x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Laboratory Analytical Instruments. If gross margin (51.9%) holds, EPS grows into the multiple faster than bears think.

RI RiskArb_Desk RQD DEBATE OPENER β€’ Hedged Event Driven 🐻 BEARISH 🎯 Target: $305.19 (-18.0%)
Spot @ $372.18

ROIC of 0.5% and an operating margin of 1.8% indicate the core business earns very little on its capital, with EV/EBITDA at 60.4 far ab

ROIC of 0.5% and an operating margin of 1.8% indicate the core business earns very little on its capital, with EV/EBITDA at 60.4 far above the 13.5 P/E.. Look at the math on BIO: paying 13.5x trailing P/E for 0.5% ROIC and 1.8% operating margins leaves zero margin of safety if Biotechnology: Laboratory Analytical Instruments demand softens. I'd wait for a retest of $327.52 before getting long.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%